Wenjuan Wang

Wenjuan Wang


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2013 in Acta Pharmacologica Sinica
Verified
Journal Article
Closed access
WWWenjuan Wang
Wenjuan Wang
LLLin-Mei Long
Lin-Mei Long
NYNeng Yang
Neng Yang
QZQing-Qing Zhang
Qing-Qing Zhang
WJWen-Jun Ji
Wen-Jun Ji
ZLZhong-Qin Liang
Zhong-Qin Liang

7 February 2019 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
WWWenjuan Wang
Wenjuan Wang
YXYajie Xiong
Yajie Xiong
XDXinyuan Ding
Xinyuan Ding
LWLong Wang
Long Wang
YZYifan Zhao
Yifan Zhao
ZLZhongqin Liang
Zhongqin Liang
Ionizing radiation (IR) is one of the major clinical therapies of cancer, although it increases the epithelial-mesenchymal transition (EMT) of non-small cell lung cancer (NSCLC), unexpectedly. The cellular and molecular mechanisms underlying this role are not completely understood. We used NSCLC cell lines as well as tumor specimens from 78 patients with NSCLC to evaluate p53, Cathepsin L (CTSL) and EMT phenotypic changes. Xenograft models was also utilized to examine the roles of mutant p53 (mut-p53) and CTSL in regulating IR-induced EMT of NSCLC. Expression of CTSL was markedly increased in human NSCLC tissues with mutant p53 (mut-p53), and p53 mutation positively correlated with metastasis of NSCLC patients. In human non-small cell lung cancer cell line, H1299 cells transfected with various p53 lentivirus vectors, mut-p53 could promote the invasion and motility of cells under IR, mainly through the EMT. This EMT process was induced by elevating intranuclear CTSL which was regulated by mut-p53 depending on Early growth response protein-1 (Egr-1) activation. In the subcutaneous tumor xenograft model, IR promoted the EMT of the cancer cells in the presence of mut-p53, owing to increase expression and nuclear transition of its downstream protein CTSL. Taken together, these data reveal the role of the mut-p53/Egr-1/CTSL axis in regulating the signaling pathway responsible for IR-induced EMT.

8 May 2020 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
SXSudong Xue
Sudong Xue
WWWei Wu
Wei Wu
ZWZiyan Wang
Ziyan Wang
GLGuangxian Lu
Guangxian Lu
JSJiantong Sun
Jiantong Sun
XDXinyuan Ding
Xinyuan Ding
Ubiquitin-specific protease 5 (USP5) is a deubiquitinating enzyme that functions as an oncoprotein in a variety of human cancers. However, the expression and role of USP5 in the metastasis of non-small cell lung cancer (NSCLC) have not been addressed. In this study, we examined the expression and prognostic significance of USP5 in NSCLC. The results revealed that USP5 was overexpressed and correlated with metastasis and overall survival in NSCLC tissues. A further in vitro study revealed that the levels of USP5 protein in NSCLC cells were associated with epithelial–mesenchymal transition (EMT) markers. Furthermore, USP5 overexpression significantly enhanced, whereas USP5 silencing significantly decreased the expression of EMT proteins and migration and invasion of NSCLC cells. In addition, the results from western blotting demonstrated that USP5 regulated EMT via the Wnt/β-catenin signaling pathway. Further immunohistochemical analysis revealed that USP5 was significantly associated with the expression of β-catenin and EMT markers in NSCLC tissues. Overall, USP5 upregulation is associated with tumor metastasis and poor prognosis in patients with NSCLC. USP5 promotes EMT and the invasion and migration of NSCLC cells. Therefore, USP5 may serve as a novel prognostic biomarker and provide a potential target for the treatment of metastasis in NSCLC.

1 February 2016 in Cancer Letters
Verified
Journal Article
Closed access
WWWenjuan Wang
Wenjuan Wang
LLLinmei Long
Linmei Long
LWLong Wang
Long Wang
CTCaihong Tan
Caihong Tan
XFXifeng Fei
Xifeng Fei
ZLZhongqin Liang
Zhongqin Liang

22 June 2015 in Acta Pharmacologica Sinica
Verified
Journal Article
Closed access
QZQing-Qing Zhang
Qing-Qing Zhang
WWWenjuan Wang
Wenjuan Wang
JLJun Li
Jun Li
NYNeng Yang
Neng Yang
GCGang Chen
Gang Chen
ZLZhong-Qin Liang
Zhong-Qin Liang

9 July 2013 in Oncology Reports
Verified
Journal Article
Open access
PDF file
THTinghua Hu
Tinghua Hu
HGHui Guo
Hui Guo
WWWenjuan Wang
Wenjuan Wang
SYShuo Yu
Shuo Yu
LHLili Han
Lili Han
KNKejun Nan
Kejun Nan
P57 and Ras homology A (RhoA) have been implicated in the growth and metastasis of several types of human cancers. This study aimed to detect their expression in hepatocellular carcinoma (HCC) tissue specimens and to determine a possible association with clinicopathological data and patient survival. A total of 80 HCC and corresponding distant normal tissue specimens were processed for immunohistochemical and qPCR analyses of p57 and RhoA expression. The data showed that expression of p57 mRNA and protein was reduced in HCC tissues when compared to that in distant non-cancer tissues (P400 ng/ml; P=0.044), larger tumor size (>5 cm, P=0.004), poor tumor differentiation (P=0.020), advanced TNM stage (P=0.027), capsule invasion (P=0.018) and tumor thrombosis (P=0.008), whereas expression of RhoA protein was significantly associated with poor tumor differentiation (P=0.042), capsule invasion (P=0.022), and tumor thrombosis (P=0.002). Furthermore, there was a strong inverse relationship between p57 and RhoA expression in HCC tissues, indicating that loss of p57 expression may contribute to RhoA overexpression in HCC tissues. The median survival time of HCC patients with p57+ and p57- expression was 13.0 and 9.0 months, respectively, whereas the median survival time of HCC patients with RhoA+ and RhoA- was 9.0 and 15.0 months. Univariate analysis revealed that the levels of AFP, tumor size, TNM stage, histological grade, capsule invasion, tumor thrombosis, p57, RhoA and co-expression of p57 and RhoA were all significant prognostic indicators for overall survival of HCC patients. Multivariate analysis showed that tumor size, TNM stage, p57, RhoA and combined loss of p57 with RhoA were risk factors for poor survival of HCC patients. This study indicates that the abnormal expression of p57 and RhoA contributes to progression of HCC and poor survival of patients.